Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions.
Thank you for standing by, and welcome to the Athersys second-quarter 2020 results Conference Call. Post-Market 0.03 (1.41%) We will alert you to important technical developments on your Find the latest Athersys, Inc. (ATHX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Posts regarding ATHX’s share price that do not foster discussion will be removed.
Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected. MESO from the largest community of traders and investors. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. Touch device users, explore by touch or with swipe gestures.Athersys to Host Second Quarter Financial Results Callvar dom1 = document.querySelector('#form1783 #field1');var field1 = new LiveValidation(dom1, {validMessage: "", onlyOnBlur: false, wait: 300});field1.add(Validate.Presence, {failureMessage:"This field is required"});field1.add(Validate.Format, {pattern: /^([^@\s]+)@((?:[-a-z0-9]+\. Copyright © 2020 MarketWatch, Inc. All rights reserved. Join Stocktwits for free stock discussions, prices, and market sentiment with millions of investors and traders. MESO 19.30 0.72 (3.88%). Do not share personal investment information or seek personal investment advice from others. This stock-market metric has correctly predicted presidential election results since 1984 ET) and the After Hours Market (4:00-8:00 p.m. Real-time trade and investing ideas on Caladrius Biosciences, Inc. CLBS from the largest community of traders and investors. Athersys Reports Second Quarter 2020 Results. ]AT CAGR of 12.13%, Translational Regenerative Medicine Market will Revenue to Cross USD 481.40 Million in 2020 to 2025Regenerative Medicine Market Size Future Scope, Demands and Projected Industry Growths to 2025Regenerative Medicine Market Size Future Scope, Demands and Projected Industry Growths to 2025Tissue Engineering Market 2020 Insights, Share, Growth and Future Trends, 2025Tissue Regeneration Market 2019 Demand Industry Growth by Forecast to 2024 – Market Research EngineLatest Update 2020: Global Tissue Engineering Market by COVID-19 Impact Analysis by Zion Market ResearchGlobal Tissue Engineering Market Estimated To Record Double-Digit Growth Over 2020-2026 - Zion Market ResearchGlobal Stem Cell and Regenerative Medicine Market is predicted to reach USD 14,745.7 Million by 2024Regenerative Medicine Market Size Future Scope, Demands and Projected Industry Growths to 2025Tissue Regeneration Market Research, Development, Top Companies, Trends And Growth 2020 To 2025Stem Cell & Regenerative Medicine Market Size, Share, Trends, CAGR by Technology, Key Players, Regions, Cost, Revenue and Forecast 2016 to 2024Tissue Regeneration Market with Covid-19 Pandemic Analysis, Growth Rate, New Trend Analysis & Forecast To 2026Regenerative Medicine Market Size, Historical Growth, Analysis, Opportunities and Forecast To 2025Regenerative Medicine Market Size Future Scope, Demands and Projected Industry Growths to 2025Cord Blood Stem Cells Market 2020 Share, Size Growing Rapidly with Recent Trends, Development, Revenue, Demand and Forecast to 2026 Says MarketReportsWorld.comTissue Engineering Market Growth Analysis, Outlook by - Trends, Opportunities and Forecast to 2025Tissue Regeneration Engineering Market to Make Great Impact in near Future by 2026Global Tissue Regeneration Engineering Market Size,Growth 2020 Global Growth, Opportunities, Trends, Regional Overview, Leading Company Analysis, And Key Country Forecast to 2026Tissue Regeneration Market 2020 - Updated For The Impact Of COVID-19 |Athersys Inc, Kinetic Concepts Inc, Organogenesis Inc During 2025 Company Address: 3201 Carnegie Ave Cleveland, Ohio 44115-2634 T: 216-431-9900 F: 216-361-9495 info@athersys.com CIK: 0001368148 Athersys, Inc. fundamental goals are to create safer and more effective new therapies that can address significant unmet medical needs and to generate substantial value for our shareholders in the process. Athersys, Inc. ATHX 2.13 0.04 (1.84%). My father left me money for a house — and my husband put his name on the deed.